highly potent nanobodies

our platform

Our single-domain antibodies are of superior specificity,  low picomolar target-binding, and high thermal stability. They are selected by phage display from camelid immune libraries, and are suitable for large-scale production in E. coli or yeast (Pichia pastoris).


Our proprietary technology is being used to develop highly potent preventive and therapeutic medications against a variety of infectious diseases, including COVID-19, MRSA, Tuberculosis and Malaria, and as well as in immuno-oncology.


VicuTec Biologicals GmbH is working in concert with the Max Planck Foundation, the Max Planck Society, the Max Planck Institute for Biophysical Chemistry, and the University Medical Center Göttingen. This cooperation is being supported by kENUP Foundation.

our products

COVID-19

Foto: John Doe
Schaltfläche

MRSA

Foto: John Doe
Schaltfläche

Tuberculosis

Foto: John Doe
Schaltfläche

Malaria

Foto: John Doe
Schaltfläche

news

EU Malaria Fund adds VicuTec to its portfolio

von keller • 18. Dezember 2020
During its 8th Session held on December 18, 2020, the Scientific Advisory Council of the EU Malaria Fund has included VicuTec Biologicals GmbH to the Fund's portfolio. The EU Malaria Fund is a public-private partnership between the European Union, International Organizations, corporations, and organized civic society, providing a novel funding instrument to address market failures in infectious diseases with significant relevance to public health globally. For more information, please click here .

Visit of the Lower-Saxonian State Secretary for Science to VicuTec

von keller • 10. Dezember 2020
Dr. Sabine Johannsen (third from right), with the Scientific Founders of VicuTec at the Max Planck Institute for Biophysical Chemistry in Göttingen / Germany.